Alyacen 7/7/7 NDC 68462-556

NDC codes

FDA NDC Directory

Product NDC (as listed)68462-556Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68462-0556Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68462-556-29	68462055629	3 BLISTER PACK in 1 CARTON (68462-556-29) / 1 KIT in 1 BLISTER PACK (68462-556-84)Marketed from Jan 19, 2012

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Alyacen 7/7/7
Generic name (nonproprietary): norethindrone and ethinyl estradiol
Dosage form: Kit
Labeler: Glenmark Pharmaceuticals Inc., USA
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 091636
Marketing start: Jan 19, 2012
Listing expires: Dec 31, 2027
Identifiers: Product ID 68462-556_9d4967e6-42df-4468-99a6-9b57499497d9SPL ID 9d4967e6-42df-4468-99a6-9b57499497d9SPL set ID 5c02b4d3-1e2f-439a-ae45-02304ee190d1RxCUI 310463, 312033, 392662, 748797, 749852, 749858, 1242786, 1242787UPC 0368462394847, 0368462394298, 0368462556849

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N468462055629 followed by a unit qualifier and the quantity

Package 68462-0556-29. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 31, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE ALYACEN 7/7/7 and ALYACEN 1/35 Tabletsare indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the NORPLANT ® System depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Table 1: Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)